Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2006_512 |
Not provided
Not provided
Not provided
The overall profile does not support development for obesity
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the effects of taranabant versus placebo on weight regain and weight maintenance after low calorie diet-induced weight loss in obese patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Placebo Comparator | Arm 1: MK0364 Pbo capsules once daily |
|
| 2 | Experimental | Arm 2: MK0364 0.5 mg capsule once daily |
|
| 3 | Experimental | Arm 3: MK0364 1 mg capsule once daily |
|
| 4 | Experimental | Arm 4: MK0364 2 mg capsule once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| taranabant | Drug | taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Body weight at 52 weeks, safety and tolerability. | 52 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Body weight, biochemical markers, blood pressure, waist circumference and patient reported outcomes at 52 weeks. | 52 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20379151 | Result | Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, Suryawanshi S, Carofano W, Johnson-Levonas AO, Shapiro DR, Kaufman KD, Heymsfield SB, Amatruda JM. A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity (Silver Spring). 2010 Dec;18(12):2301-10. doi: 10.1038/oby.2010.67. Epub 2010 Apr 8. |
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C521311 | N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: placebo | Drug | Placebo capsules once daily. Treatment for 52 weeks |
|
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001836 | Body Weight Changes |